Lv4
464 积分 2023-10-01 加入
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
2天前
已完结
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach
5天前
已完结
OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial
8天前
已完结
649P Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors
10天前
已关闭
1406 A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models
11天前
已完结
Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors
11天前
已关闭
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
12天前
已完结
642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
12天前
已完结
658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
12天前
已关闭
Abstract CT036: A first-in-human study result of a novel EGFR-targeted antibody drug conjugate (ADC) in patients with advanced nasopharyngeal carcinoma (NPC) (SYS6010-001-NPC)
12天前
已关闭
皖公网安备34019202002308
